The recently launched research project Relent aims at developing new, individualized therapies for autoimmune diseases like rheumatism and multiple sclerosis. The project will be carried out by a multidisciplinary consortium of nine scientific partners and four SME’s from Europe, the US and Australia. Among the partners is KTH Royal Institute of Technology/SciLifeLab where the research will be led by Peter Nilsson at SciLifeLab:s national facility Protein and Peptide Arrays.
“We will have the opportunity to use our expertise and technology for protein analysis and large scale investigations of autoimmune diseases in a very interesting medical context.” Said Peter Nilsson. “The constellation with a number of clinical research groups and pharma companies, with access to large and well defined panels of blood samples, together with vast knowledge about autoimmunity, is of course very interesting for us.”
Relent is funded with six million Euros for four years by the European Commission within Horizon 2020.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.